📊 INM Key Takeaways
Is INM a Good Investment? Thesis Analysis
InMed Pharmaceuticals is a pre-revenue pharmaceutical company with severely negative profitability metrics and unsustainable cash burn. The company generated only $1.9M in revenue while burning $4.0M in operating cash flow, resulting in a -205.8% free cash flow margin and deteriorating net losses. With current cash reserves of $7.0M and annual burn of $4.0M+, the company has limited runway before requiring capital restructuring or dilutive financing.
Why Buy INM? Key Strengths
- Strong liquidity position with $7.0M cash and 5.94x current ratio
- Zero long-term debt providing financial flexibility
- Modest revenue growth of 7.5% YoY indicates emerging commercialization
- Positive gross margin of 30.3% on limited revenue base
INM Investment Risks to Consider
- Massive operating losses of -$3.8M on only $1.9M revenue indicates business model failure
- Operating cash burn of $4.0M annually with only ~1.75 years of cash runway at current burn rate
- Negative ROE of -39.2% and ROA of -33.6% demonstrate severe value destruction
- Net losses worsening YoY with negative net income trend despite revenue growth
- No insider buying activity in last 90 days suggests lack of management confidence
- Pre-commercial stage with unsustainable cost structure relative to revenue generation
Key Metrics to Watch
- Quarterly revenue growth rate and path to breakeven
- Operating cash burn rate and cash runway remaining
- Gross margin expansion and operating expense reduction
- Capital raise activity and potential dilution events
INM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.94x current ratio provides a solid financial cushion.
INM Profitability Ratios
INM vs Healthcare Sector
How InMed Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INM Overvalued or Undervalued?
Based on fundamental analysis, InMed Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INM Balance Sheet & Liquidity
INM 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: InMed Pharmaceuticals Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-20.14 indicates the company is currently unprofitable.
INM Growth Metrics (YoY)
INM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $820.2K | -$1.7M | $-0.51 |
| Q1 2026 | $1.1M | -$1.7M | $-0.44 |
| Q3 2025 | $1.2M | -$1.5M | $-1.94 |
| Q2 2025 | $1.1M | -$1.5M | $-3.64 |
| Q1 2025 | $901.9K | -$1.7M | $-2.71 |
| Q2 2024 | $469.8K | -$1.5M | $-0.19 |
| Q1 2024 | $320.8K | -$2.5M | $-0.76 |
| Q3 2023 | $309.6K | -$2.0M | $-0.60 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INM Capital Allocation
INM SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for InMed Pharmaceuticals Inc. (CIK: 0001728328)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INM
What is the AI rating for INM?
InMed Pharmaceuticals Inc. (INM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INM's key strengths?
Claude: Strong liquidity position with $7.0M cash and 5.94x current ratio. Zero long-term debt providing financial flexibility.
What are the risks of investing in INM?
Claude: Massive operating losses of -$3.8M on only $1.9M revenue indicates business model failure. Operating cash burn of $4.0M annually with only ~1.75 years of cash runway at current burn rate.
What is INM's revenue and growth?
InMed Pharmaceuticals Inc. reported revenue of $1.9M.
Does INM pay dividends?
InMed Pharmaceuticals Inc. does not currently pay dividends.
Where can I find INM SEC filings?
Official SEC filings for InMed Pharmaceuticals Inc. (CIK: 0001728328) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INM's EPS?
InMed Pharmaceuticals Inc. has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INM a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, InMed Pharmaceuticals Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INM stock overvalued or undervalued?
Valuation metrics for INM: ROE of -39.2% (sector avg: 15%), net margin of -193.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INM stock in 2026?
Our dual AI analysis gives InMed Pharmaceuticals Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INM's free cash flow?
InMed Pharmaceuticals Inc.'s operating cash flow is $-4.0M, with capital expenditures of $9.3K. FCF margin is -205.8%.
How does INM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -193.5% (avg: 12%), ROE -39.2% (avg: 15%), current ratio 5.94 (avg: 2).